SG10202011023YA - Dna monoclonal antibodies targeting il-6 and cd126 - Google Patents

Dna monoclonal antibodies targeting il-6 and cd126

Info

Publication number
SG10202011023YA
SG10202011023YA SG10202011023YA SG10202011023YA SG10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA SG 10202011023Y A SG10202011023Y A SG 10202011023YA
Authority
SG
Singapore
Prior art keywords
monoclonal antibodies
antibodies targeting
dna monoclonal
dna
targeting
Prior art date
Application number
SG10202011023YA
Inventor
David Weiner
Original Assignee
Univ Pennsylvania
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, Wistar Inst filed Critical Univ Pennsylvania
Publication of SG10202011023YA publication Critical patent/SG10202011023YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10202011023YA 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126 SG10202011023YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662332377P 2016-05-05 2016-05-05

Publications (1)

Publication Number Publication Date
SG10202011023YA true SG10202011023YA (en) 2020-12-30

Family

ID=60203626

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201809786TA SG11201809786TA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126
SG10202011023YA SG10202011023YA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201809786TA SG11201809786TA (en) 2016-05-05 2017-05-05 Dna monoclonal antibodies targeting il-6 and cd126

Country Status (12)

Country Link
US (1) US20190192692A1 (en)
EP (1) EP3452106A4 (en)
JP (2) JP7311113B2 (en)
KR (2) KR20190031439A (en)
CN (1) CN109789224A (en)
AU (1) AU2024203109A1 (en)
BR (1) BR112018072697A2 (en)
CA (1) CA3023089A1 (en)
EA (1) EA201892524A1 (en)
MX (1) MX2018013523A (en)
SG (2) SG11201809786TA (en)
WO (1) WO2017192933A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635888B1 (en) 2019-03-19 2024-02-15 엘지전자 주식회사 Air purifyer
WO2022155404A1 (en) * 2021-01-14 2022-07-21 Translate Bio, Inc. Methods and compositions for delivering mrna coded antibodies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100120246A (en) * 2001-11-14 2010-11-12 센토코 오르토 바이오테크 인코포레이티드 Anti-il-6 antibodies, compositions, methods and uses
ZA200804594B (en) * 2005-12-09 2010-08-25 Ucb Pharma Sa Antibody molecules having specificity for human IL-6
MX2009001110A (en) * 2006-08-03 2009-05-11 Vaccinex Inc Anti-il-6 monoclonal antibodies and uses thereof.
CN102089326B (en) 2008-05-13 2014-12-31 诺维莫尼公司 Anti-IL-6/IL-6R antibodies and methods of use thereof
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
DK2643018T3 (en) 2010-11-23 2021-01-18 Vitaeris Inc ANTI-IL-6 ANTIBODIES FOR THE TREATMENT OF ORAL MUCOSITIS
EA201591131A1 (en) * 2012-12-13 2015-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
RU2675824C2 (en) 2013-09-11 2018-12-25 Игл Байолоджикс, Инк. Liquid protein formulations containing ionic liquids

Also Published As

Publication number Publication date
AU2024203109A1 (en) 2024-05-30
KR20230058733A (en) 2023-05-03
JP2019518074A (en) 2019-06-27
BR112018072697A2 (en) 2019-02-19
EP3452106A4 (en) 2020-01-08
EP3452106A1 (en) 2019-03-13
EA201892524A1 (en) 2019-04-30
WO2017192933A1 (en) 2017-11-09
AU2017261292A1 (en) 2018-12-20
SG11201809786TA (en) 2018-12-28
JP7311113B2 (en) 2023-07-19
CN109789224A (en) 2019-05-21
CA3023089A1 (en) 2017-11-09
KR20190031439A (en) 2019-03-26
JP2023086734A (en) 2023-06-22
MX2018013523A (en) 2019-06-10
US20190192692A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
ZA202001285B (en) Antigen-binding proteins targeting shared antigens
IL275547A (en) Antigen-binding proteins targeting shared antigens
HK1246312A1 (en) Anti-ceacam6 antibodies and uses thereof
IL262092A (en) Humanized anti-pacap antibodies and uses thereof
ZA201701920B (en) Anti-human il-17 monoclonal antibodies and use thereof
HK1251969A1 (en) Anti-her2 antibodies and methods of use
HK1259251A1 (en) Humanized anti-c1s antibodies and methods of use thereof
IL286208A (en) Humanized influenza monoclonal antibodies and methods of use thereof
HK1256816A1 (en) Novel anti-human gpvi antibodies and uses thereof
IL267271A (en) Anti-il-5 antibodies
SG10202011023YA (en) Dna monoclonal antibodies targeting il-6 and cd126
IL266059A (en) Anti-rankl antibodies and uses thereof
GB201511196D0 (en) Monoclonal antibodies